Multidisciplinary agreement on diagnosis and treatment of androgenic deficiency in aging male;Réflexion multidisciplinaire sur la prise en charge du déficit androgénique lié à l'âge

Andrologie

Volumn 13, Issue 1, 2003, Pages 11-21

  Buvat, Jacques ^b   Costa, Pierre ^b   Flam, Thierry ^b   Giuliano, François ^b   Kuhn, Jean Marc ^b   Legrand, Erick ^b   Lejeune, Hervé ^a   Mimoun, Sylvain ^b   Roger, Marc ^b   Weber, Simon ^b  

^a UNIVERSITÉ LYON 1   (France)

^b NONE

Author keywords

Aging; Androgenic deficiency; Andropause; Testosterone

Indexed keywords

ESTRADIOL; FOLLITROPIN; PROLACTIN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

AGING; ARTICLE; BODY COMPOSITION; CANCER SCREENING; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; ERYTHROPOIESIS; HEART PROTECTION; HEMATOCRIT; HORMONE DEFICIENCY; HORMONE DETERMINATION; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; METABOLISM; OSTEOPOROSIS; PATIENT MONITORING; POLYCYTHEMIA; PROSTATE CANCER; QUALITY OF LIFE; REFERENCE VALUE; RISK ASSESSMENT; SEXUALITY; SLEEP APNEA SYNDROME; TESTOSTERONE BLOOD LEVEL;

EID: 0038665571     PISSN: 11662654     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03034404     Document Type: Article

References (26)

1. ANDERSON F.H., FRANCIS R.M., PEASTON R.T., WASTELL H.J.: Androgen supplementation in eugonadal men with osteoporosis: effects of six months' treatment on markers of bone formation and resorption. J. Bone Miner. Res., 1997, 12: 472-478.
2. BAGATELL C.J., HEIMAN J.R., RIVIER J.E., BREMNER W.J.: Effects of endogenous testosterone and estradiol on sexual behavior in normal young men. J. Clin. Endocrinol. Metab., 1994, 78: 711-716.
3. BHASIN S., WOODHOUSE L., CASABURI R., et al.: Testosterone dose-response relationships in healthy young men. Am. J. Physiol. Endocrinol. Metab., 2001, 281: E1172-1181.
4. COSTA P.: Adénome prostatique, hormones et androgénothérapie. Andrologie, 2002, 12: 133-135.
5. ENGLISH K.M., STEEDS R.P., JONES T.H., DIVER M.J., CHANNER K.S.: Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: A randomized, double-blind, placebo-controlled study. Circulation, 2000, 102: 1906-1911.
6. FLAM T.: Traitement androgénique substitutif et cancer prostatique. Andrologie, 2002, 12: 136-137.
7. HAK A.E., WITTEMAN J.C., DE JONG F.H., GEERLINGS M.I., HOFMAN A., POLS H.A.: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J. Clin. Endocrinol. Metab., 2002, 87: 3632-3639.
8. HEINEMANN L.A.J., ZIMMERMANN T., VERMEULEN A., THIEL C., HUMMEL W.: A new 'aging males' symptoms' rating scale. Aging Male, 1999, 2: 105-114.
9. KIM C.Y., BUVAT J., CARSON C.C., et al.: Endocrine and metabolic aspect including treatment. In Erectile dysfunction. 1st international consultation on erectile dysfunction, July 1-3, 1999, Paris. Jardin A., Wagner G., Khoury S., Giuliano F., Padma-Nathan H., Rosen R. eds. Health Publication Ltd, Plymbridge Distributors, Plymouth, 2000: 207-240.
10. KUHN J.M.: Déficit androgénique: effet de la substitution sur la composition corporelle. Andrologie, 2002, 12: 17-23.
11. LEGRAND E., SIMON V., AUDRAN M.: Stéroides sexuels et ostéoporose chez l'homme. Andrologie, 2002, 12: 24-31.
12. LEGROS J.J., DELHEZ M.: Détection de la déficience androgénique chez l'homme de plus de 50 ans: utilisation d'une version française du test ADAM. Med. Hyg., 2002, 60: 1490-1495.
13. LEJEUNE H.: Le déficit androgénique lié à l'âge chez l'homme: terminologie, épidémiologie. Andrologie, 2002, 12: 11-16.
14. MATSUMOTO A.M.: Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J. Gerontol. A. Biol. Sci. Med. Sci., 2002, 57: M76-99.
15. MIMOUN S.: Androgènes et qualité de vie. Andrologie, 2002, 12: 257-261.
16. MORALES A., LUNENFELD B.: Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male, 2002, 5: 74-86.
17. MORLEY J.E., CHARLTON E., PATRICK P., et al.: Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism, 2000, 49: 1239-1242.
18. OH J.Y., BARRETT-CONNOR E., WEDICK N.M., WINGARD D.L.: Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care, 2002, 25: 55-60.
19. ROGER M., LAHLOU N.: Le déficit androgénique lié à l'âge: du diagnostic biologique au traitement substitutif. Andrologie, 2002, 12: 138-146.
20. ROSANO G.M., LEONARDO F., PAGNOTTA P., et al.: Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation, 1999, 99: 1666-1670.
21. SAGNIER P.P., MACFARLANE G., RICHARD F., BOTTO H., TEILLAC P., BOYLE P.: Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J. Urol., 1994, 151: 1266-1270.
22. SMITH K.W., FELDMAN H.A., MCKINLAY J.B.: Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men. Clin. Endocrinol. (Oxf), 2000, 53: 703-711.
23. SNYDER P.J., PEACHEY H., HANNOUSH P., et al.: Effect of testosterone treatment on bone mineral density in men over 65 years of age. J. Clin. Endocrinol. Metab., 1999, 84: 1966-1972.
24. SNYDER P.J., PEACHEY H., HANNOUSH P., et al.: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J. Clin. Endocrinol. Metab., 1999, 84: 2647-2653.
25. SZULC P., MUNOZ F., CLAUSTRAT B., et al.: Bioavailable estradiol may be an important determinant of osteoporosis in men: the MINOS study. J. Clin. Endocrinol. Metab., 2001, 86: 192-199.
26. WANG C., SWEDLOFF R.S., IRANMANESH A., et al.: Long term efficacy and safety of transdermal testosterone gel (Androgel) in hypogonadal men. The Endocrine Society's 84th Annual Meeting, 2002, Abstract: P2-646.